London, April 25, 2026, 21:06 BST
- Haleon shares finished the day up in London on Friday, clawing back some ground after a spell of weakness.
- Q1 2026 trading numbers from the Sensodyne and Panadol maker are expected out April 29.
- Eyes are on U.S. demand, cold-and-flu product sales, and if that 2026 guidance still stands.
Haleon PLC picked up 1.02% to finish Friday at 355.20p in London trading, ahead of what’s expected to be a busy stretch for the consumer-health company. Still, the shares showed a 0.95% drop over the last five sessions and remain 5.23% lower year-to-date, according to MarketScreener data.
April 29 is on the radar, with Haleon set to deliver its first trading update since outlining a 3% to 5% organic revenue growth goal for 2026. Organic growth, which excludes impacts from currency shifts and acquisitions, helps investors focus on core sales performance. The company’s 2026 annual meeting lands on the same date, according to its calendar.
North America stands out as the challenge. Back in February, Chief Executive Brian McNamara told Reuters he was “confident the U.S. will grow this year.” He also said Haleon is targeting a return to its medium-term growth range of 4% to 6% by 2027, following shifts in regional leadership and changes to distribution. Reuters
Haleon counts Sensodyne, Panadol, Centrum, and Voltaren among its lineup. Its products span oral health, vitamins and supplements, pain relief, respiratory, digestive, and skin health—giving the company a foot in categories with consistent, everyday sales as well as those that spike with cold-and-flu season.
Haleon started Friday at 352.10p, slipping as low as 350.40p and peaking at 356.40p. Roughly 16.6 million shares changed hands, according to Investing.com data.
The shareholder deadline came and went on Friday. Haleon locked in April 24 as the cutoff for investors wanting to opt in to its dividend reinvestment plan for the 2025 final payout. Through the DRIP, shareholders can channel their cash dividend directly into additional shares. The final dividend stands at 4.9p per ordinary share, scheduled for payment on May 14.
The 2026 setup isn’t just about sales; profit is front and center, too. Haleon posted 2025 organic revenue growth of 3.0%, with total revenue hitting £11.03 billion and adjusted operating profit at £2.53 billion. For the year, £500 million goes to share buybacks. Adjusted operating profit strips out items like transaction-related and restructuring costs.
The risks are straightforward. If this cold-and-flu season underwhelms again, or U.S. consumers hold back—or just turn to lower-priced alternatives—the April update might sit awkwardly with any talk of a rebound, even with buybacks propping up per-share earnings.
Peer updates haven’t offered much relief. Reckitt, the company behind Mucinex and Dettol, reported on April 22 that core like-for-like sales edged up just 1.3% in the first quarter, blaming “very low seasonal incidence.” Like-for-like measures sales on a broadly comparable basis. CEO Kris Licht pointed out that stripping out seasonal over-the-counter products, growth was 3.1%. Those over-the-counter products are sold without a prescription. Reckitt
Harsharan Mann at Aviva Investors, speaking to Reuters after Reckitt’s latest update, called the results “broad-based muted growth”—exactly what she’s bracing for among other consumer staples this quarter. Over at JPMorgan, analyst Celine Pannuti flagged concerns that Reckitt’s performance puts its full-year goals in question. Reuters
Kenvue, which owns Tylenol and Listerine, told investors Thursday it’s set to release first-quarter results before the bell on May 7, but won’t be hosting its usual call due to its pending deal with Kimberly-Clark. The update drops just after Haleon’s, adding another data point for consumer-health watchers.
Haleon’s April 29 focus comes down to a single point: can strength in oral care and growth in emerging markets make up for sluggish U.S. discretionary health and respiratory categories? Should volumes disappoint once more, a buyback won’t fix the sales dilemma.
